Acetylcysteine

Generic Name: Acetylcysteine

Brand Names: Acetadote

Drug Type: Small Molecule

Chemical Formula: C_₅H_₉NO_₃S

CAS Number: 616-91-1

Unique Ingredient Identifier: WYQ7N0BPYC

Background: Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.

Acetylcysteine was granted FDA approval on 14 September 1963.

Indication: Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.

Associated Conditions: Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis

Associated Therapies: Airway secretion clearance therapy

Clinical Trials

Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels

Phase 1

Recruiting

Conditions: Mitochondrial Disease

Interventions: Drug: N-Acetylcysteine

First Posted Date: 2022-02-15

Last Posted Date: 2023-03-22

Lead Sponsor: Michio Hirano, MD

Target Recruit Count: 18

Registration Number: NCT05241262

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

Phase 1

Recruiting

Conditions: Polycythemia Vera
Myelofibrosis
Myeloproliferative Neoplasm
Essential Thrombocythemia
MPN

Interventions: Drug: N-Acetylcysteine

First Posted Date: 2021-11-17

Last Posted Date: 2024-01-18

Lead Sponsor: University of California, Irvine

Target Recruit Count: 27

Registration Number: NCT05123365

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
🇺🇸
University of California, Irvine, Irvine, California, United States

A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma

Phase 1

Recruiting

Conditions: Lymphoma

Interventions: Drug: N-Acetylcysteine

First Posted Date: 2021-10-18

Last Posted Date: 2024-10-31

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 32

Registration Number: NCT05081479

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

NAC for Attenuation of COVID-19 Symptomatology

Phase 2

Not yet recruiting

Conditions: Covid19
COVID-19 Lower Respiratory Infection
SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
Oxidative Stress
COVID-19 Pneumonia
SARS-CoV-2 Acute Respiratory Disease
COVID-19 Respiratory Infection
SARS-CoV2 Infection

Interventions: Other: Placebo
Drug: N-acetylcysteine

First Posted Date: 2021-10-12

Last Posted Date: 2023-08-07

Lead Sponsor: Cambridge Health Alliance

Target Recruit Count: 200

Registration Number: NCT05074121

Locations: 🇺🇸
Cambridge Health Alliance, Everett, Massachusetts, United States

Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold

Phase 3

Not yet recruiting

Conditions: Common Cold

Interventions: Drug: Acetylcysteine
Drug: Paracetamol
Drug: Phenylephrine

First Posted Date: 2021-10-07

Last Posted Date: 2024-08-07

Lead Sponsor: Sandoz

Target Recruit Count: 1002

Registration Number: NCT05070650

Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei

Phase 1

Conditions: Pseudomyxoma Peritonei

Interventions: Drug: Bromelin
Drug: N-Acetylcysteine

First Posted Date: 2021-07-29

Last Posted Date: 2022-06-02

Lead Sponsor: Maimónides Biomedical Research Institute of Córdoba

Target Recruit Count: 10

Registration Number: NCT04982146

Locations: 🇪🇸
Hospital Universitario Reina Sofía, Córdoba, Spain

A Study of NAC for AUD

Phase 2

Withdrawn

Conditions: Alcohol Use Disorder

Interventions: Drug: N-acetylcysteine
Drug: Placebo

First Posted Date: 2021-07-16

Last Posted Date: 2023-07-21

Lead Sponsor: Uniformed Services University of the Health Sciences

Registration Number: NCT04964843

Outcomes of Patients After Allo-HSCT With Decitabine and NAC

Phase 3

Not yet recruiting

Conditions: Engraft Failure
Relapse
GVHD

Interventions: Drug: decitabine
Drug: Cytarabine
Drug: Acetylcysteine
Drug: Busulfan
Drug: Semustine
Drug: Cyclophosphamide
Drug: Mycophenolate
Drug: Cyclosporin A
Drug: Anti-thymocyte globulin

First Posted Date: 2021-06-30

Last Posted Date: 2021-06-30

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 100

Registration Number: NCT04945096

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

Phase 2

Conditions: Acute Ischemic Stroke

Interventions: Drug: Dextrose in Water
Drug: Acetylcysteine

First Posted Date: 2021-06-09

Last Posted Date: 2021-06-11

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 118

Registration Number: NCT04918719

Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients

Phase 3

Completed

Conditions: Corona Virus Disease 19 (Covid19)
Corona Virus Infection
Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV2)

Interventions: Drug: N-acetylcysteine

First Posted Date: 2021-03-10

Last Posted Date: 2022-04-27

Lead Sponsor: Ain Shams University

Target Recruit Count: 60

Registration Number: NCT04792021

Locations: 🇪🇬
Al Assema Hospital, Cairo, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy